Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,012

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,012 results for “neurological”

Learn how ShareScore rates datasets ↗
geo24/100

High-Throughput Drug Discovery for a Rare Neurological Disorder: Uncovering a Novel Therapeutic Opportunity for the 19q12 Autism Spectrum Disorder [19q12 neurons baseline data]

GEO Series GSE292758. Homo sapiens. 5 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2025View details →
geo24/100

Loss of Neurological Disease HSAN-I-Associated Gene SPTLC2 Impairs CD8+ T Cell Responses to Infection by Inhibiting T Cell Metabolic Fitness

GEO Series GSE112715. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2019View details →
geo24/100

Comprehensive Analysis of TCR-β Repertoire in Patients with Neurological Immune-mediated Disorders

GEO Series GSE121082. Homo sapiens. 106 samples. Type: Other.

openGEO-OpenJan 2019View details →
geo24/100

TEFM variants impair mitochondrial transcription elongation causing childhood-onset neurological disease

GEO Series GSE185245. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2022View details →
geo24/100

Hippocampal and neocortex transcriptome sequencing data from 17 mesial temporal lobe epilepsy patients and 2 neocortex samples from neurologically healthy controls

GEO Series GSE134697. Homo sapiens. 36 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJul 2019View details →
geo24/100

Multi-tissue DNA methylation analysis to identify an appropriate surrogate tissue for a unique neurological tissue specific to spina bifida

GEO Series GSE313496. Homo sapiens. 81 samples. Type: Methylation profiling by genome tiling array.

openGEO-OpenJan 2026View details →
zenodo24/100

Figure 2 from: Drenska M, Elitova S, Grigorova V, Naseva E, Getov I (2019) Analysis of primary outpatient data for off-label use of medicines in neurology. Pharmacia 66(4): 165-170. https://doi.org/10.3897/pharmacia.66.e36620

Figure 2 Type of off-label use.

opencc-by-4.0Jan 2020View details →
zenodo24/100

Figure 1 from: Drenska M, Elitova S, Grigorova V, Naseva E, Getov I (2019) Analysis of primary outpatient data for off-label use of medicines in neurology. Pharmacia 66(4): 165-170. https://doi.org/10.3897/pharmacia.66.e36620

Figure 1 Off-label use with regard to patients and prescriptions.

opencc-by-4.0Jan 2020View details →
zenodo24/100

Neurologic morbidity and functional independence in adult survivors of childhood cancer

<p>SAS data set "<span><a href="../api/records/10878104/draft/files/neuro_morbi_indep.sas7bdat/content" target="_blank" rel="noopener noreferrer">neuro_morbi_indep.sas7bdat</a></span>" contains data for publication "Neurologic morbidity and functional independence in adult survivors of childhood cancer". Variables and formats are in the file "<span><a href="../api/records/10878104/draft/files/Variables%20and%20formats%20for%20neuro_morbi_indep.docx/content" target="_blank" rel="noopener noreferrer">Variables and formats for neuro_morbi_indep.docx</a></span>".</p>

opencc-by-4.0Nov 2023View details →
dryad24/100

Data from: Education research: simulation training for neurology residents on acquiring tPA consent: an educational initiative

[No abstract entered]

opencc-zeroDec 2017View details →
zenodo24/100

Clinical course of neurologic adverse events associated with immune checkpoint inhibitors

<p>In the present dataset we collected clinical, demographic and outcome data of a large cohort of patients with neurological immune-related adverse events associated with immune check-point inhibitors.&nbsp;&nbsp;</p>

openJun 2024View details →
zenodo24/100

BIOMARKERS OF ATHEROGENESIS AND CLINICAL NEUROLOGICAL CHARACTERISTICS OF THE INTERNAL CAROTY ARTERY

<p><em><span>Atherosclerosis is a multifactorial and widespread process that underlies the development of cardiovascular and cerebrovascular diseases. Atherosclerotic damage of cerebral vessels is a long-term process that passes through several stages during its development, in particular, the "asymptomatic" stage. Considering that atherosclerotic damage of carotid arteries is widely important in the development of acute cerebrovascular disorders, atherosclerotic damage of internal carotid arteries in patients with asymptomatic stenosis was generally considered as a model of atherosclerosis in brachiocephalic arteries (BSA). In this article, clinical-neurological and dopplerographic indicators of the development of the atherosclerotic process in patients with asymptomatic stenosis of the carotid artery are evaluated.</span></em></p>

openSep 2024View details →
dryad24/100

Data from: A new way to estimate neurologic disease prevalence in the United States

Objective: Considerable gaps exist in knowledge regarding the prevalence of neurologic diseases, such as multiple sclerosis (MS), in the United States. Therefore, the MS Prevalence Working Group sought to review and evaluate alternative methods for obtaining a scientifically valid estimate of national MS prevalence in the current health care era. Methods: We carried out a strengths, weaknesses, opportunities, and threats (SWOT) analysis for 3 approaches to estimate MS prevalence: population-based MS registries, national probability health surveys, and analysis of administrative health claims databases. We reviewed MS prevalence studies conducted in the United States and critically examined possible methods for estimating national MS prevalence. Results: We developed a new 4-step approach for estimating MS prevalence in the United States. First, identify administrative health claim databases covering publicly and privately insured populations in the United States. Second, develop and validate a highly accurate MS case-finding algorithm that can be standardly applied in all databases. Third, apply a case definition algorithm to estimate MS prevalence in each population. Fourth, combine MS prevalence estimates into a single estimate of US prevalence, weighted according to the number of insured persons in each health insurance segment. Conclusions: By addressing methodologic challenges and proposing a new approach for measuring the prevalence of MS in the United States, we hope that our work will benefit scientists who study neurologic and other chronic conditions for which national prevalence estimates do not exist.

opencc-zeroDec 2018View details →
zenodo24/100

Effect of neurological screening on early dementia detection in southern Italy

<p>Objective</p> <p>Population screening can facilitate early diagnosis of dementia and improve disease management. This study examined the effects of a screening campaign for neurodegenerative disorders on the early diagnosis of dementia using 2-year follow-up data.</p> <p>Methods</p> <p>A 5-day screening campaign was conducted that comprised neurological, neuropsychological and other specialist examinations. Identification of alterations during the neurological examination was followed-up by further diagnostic examinations to confirm the neurological impairment.</p> <p>Results</p> <p>Neurological alterations were observed in 39% of the screened subjects, who were mostly diagnosed with mild cognitive impairment and referred to a dementia and cognitive disorders centre. Suspicion of neurological impairment was a risk factor for inclusion in a specific neurological ambulatory follow-up and a condition for exemption from payment for medical examinations.</p> <p>Conclusions</p> <p>Neurodegenerative screening initiatives should include subjects selected by general practitioners. It would be useful to create a network including primary care physicians and cognitive disorder centres. Telemedicine tools (e.g., teleconsulting) could also be used to facilitate early diagnosis.</p>

opencc-by-4.0Oct 2020View details →
dryad24/100

One comprehensive clinical neurologic examination is sufficient to declare brain death

<p>Objective: To fill the evidence gap on the value of a single (SBD) or dual brain death (DBD) exam by providing data on irreversibility of brain function, organ donation consent and transplantation  </p> <p>Methods: 12-year tertiary hospital and organ procurement organization data on brain death (BD) were combined and outcomes, including consent rate for organ donation and organs recovered and transplanted after SBD and DBD were compared after multiple adjustments for co-variates </p> <p>Results: two-hundred sixty-six patients were declared BD, 122 after SBD and 144 after DBD. Time from event to BD declaration was longer by an average of 20.9 hours after DBD (p=0.003). Seventy-five (73%) families of patients with SBD and 86 (72%) with DBD consented for organ donation (p=0.79). The number of BD exams was not a predictor for consent. No patient regained brain function during the periods following BD. Patients with SBD were more likely to have at least one lung transplanted (p = 0.033). The number of organs transplanted was associated with the number of exams [beta coefficient, (95% CI) -0.5 (-0.97 to -0.02), p=0.044], along with age (for 5 year increase, -0.36 (-0.43 to -0.29), p&lt;0.001) and PaO2 level (for 10 mmHg increase, 0.026 (0.008 to 0.044), p=0.005) and decreased as the elapsed time to BD declaration increased (p=0.019). </p> <p>Conclusions:  A single neurologic examination to determine brain death is sufficient in patients with non-anoxic catastrophic brain injuries. A second examination is without additional yield in this group and its delay reduces the number of organs transplanted. </p>

opencc-zeroOct 2021View details →
ClinicalTrials.gov24/100

Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon)

ClinicalTrials.gov study NCT02876289. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients

ClinicalTrials.gov study NCT01149148. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations

ClinicalTrials.gov study NCT02858167. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Correlation of Motor Metrics and Neurological Data

ClinicalTrials.gov study NCT05462080. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Kundalini Yoga & Healthy Neurological Aging

ClinicalTrials.gov study NCT04726072. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.